Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Yale Cancer Center scientists discover molecular key to how cancer spreads
Yale Cancer Center researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.
Alessandro Santin Recognized as 2019 ASCO Leader in Cancer Care
Research by Alessandro Santin, M.D., professor of gynecology, obstetrics & reproductive sciences and leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and Yale Cancer Center, has had his research selected as one of the top five advances of the year by the American Society of Clinical Oncology (ASCO).
Yale Study Finds Link Between Medicaid Expansion and Equity in Cancer Care
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act (ACA), according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
A Successful Form of Immunotherapy For Blood Cancers Shows Promise For Other Types of the Disease
An innovative new immunotherapy treatment at the Yale Cancer Center and Smilow Cancer Hospital called CAR T-cell therapy has shown remarkable success in treating certain blood cancers, including some for which all other treatment options have failed.Source: Connecticut Magazine
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
National Cancer Center Partnership Expected to Advance Cancer Research at YSPH, Yale
A new partnership with the National Cancer Center of China will provide opportunities for collaborative research, clinical trials and workforce training at the Yale School of Public Health, Yale Cancer Center and Yale Institute for Global Health.
Yale Cancer Center Scientists Receive Grant to Advance Lung Cancer Research
Katerina Politi, PhD and Don Nguyen, PhD, members of the Signal Transduction Research Program at Yale Cancer Center (YCC), have received a 5-year, nearly $4 million National Cancer Institute (NCI) grant to support Lung Cancer research.
Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Complex cancer surgery is safer at brand name cancer hospitals compared to the affiliate hospitals that share their brand
A new study by Yale Cancer Center (YCC) researchers shows complex cancer surgery is safer at brand name cancer hospitals than at affiliated hospitals that share the top-notch brand names.
Scientists find another way HIV can hide from vaccines
A Yale-led team has discovered yet another molecular trick HIV uses to survive immune system attacks, a finding that may influence efforts to develop an effective vaccine against HIV/AIDS. The virus forms specifically shaped structures called trimers on its surface, which are designed to attach to and infect cells and produce more HIV. To escape the immune system, the trimer can change shapes over time into three separate conformations. Vaccines now under development target one form of those structures in order to spur an immune system response. However, the new study published April 10 in the journal Nature shows that the HIV may escape immune system detection by hiding in yet another trimer conformation, called State 1.
High-dose Vitamin D Shows Benefit in Patients with Advanced Colorectal Cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease. The findings, by researchers from Yale Cancer Center and Dana-Farber Cancer Institute, are published in the Journal of the American Medical Association (JAMA).
Researchers Have Found that Certain Inherited Epigenetic Changes Can Lead to Increased Cancer Rates
Cancers have a habit of running in the family. This is due in large part to the inheritance of versions of genes that are linked with cancer, but some researchers are investigating another heritable risk factor: epigenetic modifications. These are not changes in the DNA sequence of a gene itself but processes that change a DNA sequence’s accessibility or ability to be expressed. These changes can regulate gene expression, and in certain circumstances, be passed down from parent to child alongside the genes they regulate.
New Tool Helps Find Genetic Culprits in Cancer’s Spread
The ability of cancer to establish itself in distant parts of the body — called metastasis — causes 90% of deaths from solid tumors. Metastasis is the result of complex genetic interactions that have proven difficult for scientists to study. Now Yale researchers have devised a way to identify some of the most dangerous of those interactions.
Smilow Cancer Hospital first in Connecticut to perform CAR T-cell therapy
One of the most promising new generations of cancer treatment called Chimeric Antigen Receptor (CAR) T-cell therapy is now available for patients at Smilow Cancer Hospital. CAR T-cell therapy is groundbreaking immunotherapy that can cure patients with certain blood cancers who have run out of treatment options. In Connecticut, the treatment is only available at Smilow Cancer Hospital in partnership with Yale Cancer Center.
Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Yale Cancer Center Researchers Find Treatment for Rare Blood Cancer Saves Lives, but Is Underused
Clinical trials have pointed a way toward treatment of essential thrombocythemia (ET), a rare, incurable cancer caused by massive overproduction of blood platelets. But the use and benefit of the therapy, hydroxyurea (HU), which suppresses formation of blood cells, had never been studied in a “real world” setting. Researchers at Yale Cancer Center now report that HU significantly reduces risk of thrombotic events including venous thrombosis, strokes, and heart attacks and lowers death rates in patients who use it.